Price
No data yet.
Social Signal Score
Analyst Ratings
6 analystsRevenue
$1.22T+192.69%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Julie So-Young Kim
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 47,029
- Beta
- 0.09
- Country
- JP
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 1.17
Financials
Revenue
$1.22T+192.7%Net Income
$113.20B+356.9%EBITDA
$337.49B+358.6%Free Cash Flow
$73.81B+93.0%EPS (diluted)
$35.27+123.1%Shares Outstanding (diluted)
3.21B+104.7%Operating Expenses
$453.91BCash & Debt
$527.58BReturn of Capital
$151.14BRevenue by Segment (annual)
$4.51TDividend per Share
$0.31Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $4.78T | $203.33B | $63.91 |
| 2024 | $4.58T | $107.93B | $34.17 |
| 2023 | $4.26T | $144.07B | $46.05 |
| 2022 | $4.03T | $317.02B | $102.15 |
| 2021 | $3.57T | $230.06B | $73.57 |
| 2020 | $3.20T | $376.00B | $120.36 |
| 2019 | $3.29T | $44.24B | $14.21 |
| 2018 | $2.10T | $109.13B | $34.78 |
| 2017 | $1.77T | $186.89B | $119.68 |
| 2016 | $1.73T | $114.94B | $73.58 |
| 2015 | $1.81T | $80.17B | $51.13 |
| 2014 | $1.78T | $-145.78B | $-46.47 |
| 2013 | $1.69T | $106.66B | $67.55 |
| 2012 | $1.56T | $131.24B | $94.11 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from TAK's reported EPS growth of -2.9% a year over 13 years.
- EPS in 5 years
- $55.71
- Implied price
- $2,563
- Return from $17.86
- 170.0% a year
To earn 15.0% a year on these assumptions you'd need to buy at $1,274 — today's price is already 98.6% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 32 | 39 | 46 | 53 | 60 |
|---|---|---|---|---|---|
| -12.9% | 125.2% | 134.3% | 142.2% | 149.2% | 155.4% |
| -7.9% | 138.2% | 147.8% | 156.1% | 163.5% | 170.1% |
| -2.9% | 151.1% | 161.2% | 170.0% | 177.8% | 184.7% |
| 2.1% | 164.0% | 174.7% | 183.9% | 192.1% | 199.4% |
| 7.1% | 177.0% | 188.1% | 197.8% | 206.4% | 214.1% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
145+107.14%Social Signal Score
Mentions (6)
- Newsseekingalpha.com·21d ago·Positive
Takeda Pharmaceutical Company Limited (TAK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Takeda Pharmaceutical Company Limited (TAK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsbusinesswire.com·22d ago·Negative
…n Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) under Priority Review for zasocitinib (TAK-279) for the treatment of adults with moderate-to-severe plaque psoriasis. Zasocitinib is an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) in…
View source ↗ - Newsreuters.com·38d ago·Negative
US FDA approves Takeda, Protagonist's drug for rare blood cancer The U.S. Food and Drug Administration has approved a first-of-its-kind drug from Takeda Pharmaceutical and Protagonist Therapeutics to treat a rare blood cancer, the health regulator said on Friday.
View source ↗ - Newsbusinesswire.com·43d ago·Positive
… in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1 OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease …
View source ↗ - Newszacks.com·48d ago·Neutral
Wall Street Analysts Think Takeda Pharmaceutical Co. (TAK) Could Surge 26.41%: Read This Before Placing a Bet The consensus price target hints at a 26.4% upside potential for Takeda Pharmaceutical Co. (TAK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
View source ↗ - Newszacks.com·49d ago·Positive
Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
View source ↗
Earnings
Thu, Oct 29(in 3 weeks)
Consensus estimate $0.15 per share
Typical surprise -85.6% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Jul 30$0.23 vs $0.17beat
- Wed, May 13$-0.05 vs $0.21miss
- Thu, Jan 29$0.21 vs $0.55miss
- Thu, Oct 30$-0.02 vs $0.44miss
- Wed, Jul 30$0.52 vs $0.47beat
- Thu, May 8$-0.22 vs $0.24miss
Estimates and results for TAK via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by TAK officers and directors.
- Bought
- —
- Sold
- $13.1m
0 trades
20 trades
- Duprey Lauren Rusckowskisold
- Plump Andrew Stewartsold
- Plump Andrew Stewartsold
- Greenway Nicola Deidre Petalsold
- Shannon Elaine Marysold
- Farajallah Awny Samaan Botrossold
- Ibrahim Ramy Riad Ahmedsold
- Pacheco Rhonda Janicesold
80 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Virginia Ann Foxxhouse · NC05 · disclosed Sep 5, 2023 (7d later)Sell$15,001 - $50,000
- Daniel Goldmanhouse · NY10 · disclosed Aug 13, 2023 (34d later)Sell$15,001 - $50,000
- Ro Khannahouse · CA17 · disclosed Apr 7, 2023 (28d later)Buy$1,001 - $15,000
- Daniel Goldmanhouse · NY10 · disclosed Mar 20, 2023 (21d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Mar 8, 2023 (26d later)Buy$15,001 - $50,000
- Virginia Ann Foxxhouse · NC05 · disclosed Mar 3, 2023 (15d later)Buy$1,001 - $15,000
- Virginia Ann Foxxhouse · NC05 · disclosed Dec 6, 2022 (35d later)Buy$1,001 - $15,000
- Greg Gianfortehouse · MT00 · disclosed Oct 20, 2019 (39d later)Sell$1,001 - $15,000
- Van Taylorhouse · TX03 · disclosed Apr 15, 2019 (21d later)Sell$15,001 - $50,000
- Greg Gianfortehouse · MT00 · disclosed Jan 23, 2019 (33d later)Buy$15,001 - $50,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.